MedTrace Logo

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

NCT07347405 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-12

No results posted yet for this study

Summary

The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Psilocybin 10 mg

Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.

DRUG

Psilocybin 20 mg

Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.

DRUG

Psilocybin 30 mg

Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.

Sponsors & Collaborators

  • Arizona Biomedical Research Commission (ABRC)

    collaborator OTHER

  • Francisco A Moreno

    lead OTHER

Principal Investigators

  • Francisco Moreno, MD · University of Arizona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2028-01-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07347405 on ClinicalTrials.gov